Gynecologic Oncology

Papers
(The H4-Index of Gynecologic Oncology is 38. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
Editorial board118
Cytology-negative, non-myoinvasive stage IC serous endometrial cancer: Assessment of adjuvant chemotherapy omission112
Physical activity and lower extremity lymphedema among endometrial cancer survivors: A population-based cross-sectional study96
Validating the predicted impact of HPV vaccination on HPV prevalence, cervical lesions, and cervical cancer: A systematic review of population level data and modelling studies83
Corrigendum to “Chemotherapy response score (CRS) as a surrogate marker for homologous recombination deficiency (HRD) based on loss of heterozygosity (LOH) in high grade serous ovarian cancer (HGSOC) 82
Perioperative outcomes after interval cytoreductive surgery and primary cytoreductive surgery for advanced epithelial ovarian cancer in Australia: A National Gynae-Oncology Registry (NGOR) study81
A conceptual model of vulnerability to care delay among women at risk for endometrial cancer81
Molecular comparison reveals distinct transcriptomic differences between uterine carcinosarcoma and papillary serous carcinoma distinguishable by DNA damage71
The role of neoadjuvant chemotherapy in advanced-stage clear cell ovarian cancer: A GCIG multi-institutional retrospective cohort study67
2025 Annual Meeting on Women's Cancer – SGO Meeting Insights64
Prognosis of patients who become pregnant after achieving a complete response with fertility-sparing treatment in early endometrial cancer: A Gynecologic Oncology Research Investigators Collaboration 63
Uterine cancer incidence overtakes colorectal cancer, disproportionately impacting minority women in the United States61
Molecular testing in the upfront setting for high-grade endometrial cancer: How are we doing?60
Quantifying opportunities to reduce high-grade serous ovarian cancer via opportunistic salpingectomy58
Investigating the role of the poly (ADP-ribose) polymerase enzyme family in cervical cancer pathogenesis55
Ovarian-Adnexal Reporting and Data System (O-RADS) for adnexal masses: Are we hitting the mark?55
Obesity and ovarian cancer: Leveraging real-world data for incidence and outcomes using a multicenter nationwide electronic database54
Combination of BVAC-C and durvalumab in recurrent or metastatic cervical cancer: A phase II study54
A phase I, first-in-human, dose escalation and expansion study to evaluate the safety and tolerability of XmAb541 (Claudin 6 x CD3) T-cell engaging bispecific antibody in advanced solid tumors52
Trends in FDA approval of novel therapies in women's cancer: A study of the last 25 years51
(ENCORE) Long-term safety and efficacy of selinexor maintenance treatment in patients with TP53 wild-type advanced or recurrent endometrial cancer: Follow-up subgroup analysis of the ENGOT-EN5/GOG-30549
Clear cell carcinoma of cervix and vagina: A review of 63 cases in the post-diethylstilbestrol era49
Preoperative brachytherapy of early-stage cervical cancer: A multicenter study by the SFRO brachytherapy group48
Endometrial cancer survivors' perceptions of their cardiovascular disease risk (results from WF-1804CD AH-HA)48
Prognostic value of HE4 in advanced-stage, high-grade serous ovarian cancer: Analysis of HE4 kinetics during NACT, predicting surgical outcome and recurrence in comparison to CA12547
Recurrence and survival in endometrioid endometrial cancer - a population-based cohort study47
The promise and perils of biomarker testing in gynecologic cancers46
Retrospective analysis of clinical features and fertility outcomes with fertility-sparing treatment of placental site trophoblastic tumor46
Preclinical in vitro and in vivo activity of the RAF/MEK clamp avutometinib in combination with FAK inhibition in uterine carcinosarcomas44
Racial disparities in human papillomavirus vaccination rates and correlation with cervical cancer stage at diagnosis: A retrospective analysis43
ChatGPT vs Google: Understanding a patient's perspective on their cancer diagnosis, recommended treatment, and survival outcomes41
Patient-reported outcomes of maintenance rucaparib in patients with recurrent ovarian carcinoma in ARIEL3, a phase III, randomized, placebo-controlled trial41
Clinical trial screening in gynecologic oncology: Defining the need and identifying best practices41
Quality-adjusted survival in women with gynecologic malignancies receiving IMRT after surgery: A Ppatient Rreported Ooutcome study of NRG oncology's RTOG 120340
Targeting master regulators with general transcription inhibitors in clear cell ovarian cancer40
Consensus statements and treatment algorithm to guide clinicians in the selection of maintenance therapy for patients with newly diagnosed, advanced ovarian carcinoma: Results of a Delphi study40
Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer39
Endometrial stripe thickness at the time of diagnosis of uterine papillary serous carcinoma in black patients (2137)38
0.19481492042542